Literature DB >> 32703821

What is behind programmatic treatment outcome definitions for tuberculosis?

Zaza Avaliani1, Ogtay Gozalov2, Giorgi Kuchukhidze2, Alena Skrahina3, Viorel Soltan4, Martin van den Boom2, Irina Vasilyeva5, Valentina Vilc6, Askar Yedilbayev7.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32703821     DOI: 10.1183/13993003.01751-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  4 in total

1.  Clinical standards for drug-susceptible pulmonary TB.

Authors:  O W Akkerman; R Duarte; S Tiberi; H S Schaaf; C Lange; J W C Alffenaar; J Denholm; A C C Carvalho; M S Bolhuis; S Borisov; J Bruchfeld; A M Cabibbe; J A Caminero; I Carvalho; J Chakaya; R Centis; M P Dalcomo; L D Ambrosio; M Dedicoat; K Dheda; K E Dooley; J Furin; J-M García-García; N A H van Hest; B C de Jong; X Kurhasani; A G Märtson; S Mpagama; M Munoz Torrico; E Nunes; C W M Ong; D J Palmero; R Ruslami; A M I Saktiawati; C Semuto; D R Silva; R Singla; I Solovic; S Srivastava; J E M de Steenwinkel; A Story; M G G Sturkenboom; M Tadolini; Z F Udwadia; A R Verhage; J P Zellweger; G B Migliori
Journal:  Int J Tuberc Lung Dis       Date:  2022-07-01       Impact factor: 3.427

2.  Clinical standards for the assessment, management and rehabilitation of post-TB lung disease.

Authors:  G B Migliori; F M Marx; N Ambrosino; E Zampogna; H S Schaaf; M M van der Zalm; B Allwood; A L Byrne; K Mortimer; R S Wallis; G J Fox; C C Leung; J M Chakaya; B Seaworth; A Rachow; B J Marais; J Furin; O W Akkerman; F Al Yaquobi; A F S Amaral; S Borisov; J A Caminero; A C C Carvalho; D Chesov; L R Codecasa; R C Teixeira; M P Dalcolmo; S Datta; A-T Dinh-Xuan; R Duarte; C A Evans; J-M García-García; G Günther; G Hoddinott; S Huddart; O Ivanova; R Laniado-Laborín; S Manga; K Manika; A Mariandyshev; F C Q Mello; S G Mpagama; M Muñoz-Torrico; P Nahid; C W M Ong; D J Palmero; A Piubello; E Pontali; D R Silva; R Singla; A Spanevello; S Tiberi; Z F Udwadia; M Vitacca; R Centis; L D Ambrosio; G Sotgiu; C Lange; D Visca
Journal:  Int J Tuberc Lung Dis       Date:  2021-10-01       Impact factor: 3.427

3.  The absence of evidence of cure is not a risk for recurrent TB among patients treated for TB.

Authors:  L Mantshonyane; B Kgwaadira; R Gross
Journal:  Int J Tuberc Lung Dis       Date:  2021-06-01       Impact factor: 3.427

4.  Analysis of Factors Influencing Multidrug-Resistant Tuberculosis and Validation of Whole-Genome Sequencing in Children with Drug-Resistant Tuberculosis.

Authors:  Ying Zhang; Ruiqiu Zhao; Zhenzhen Zhang; Quanbo Liu; Aihua Zhang; Qiaoli Ren; Siyuan Li; Xiaoru Long; Hongmei Xu
Journal:  Infect Drug Resist       Date:  2021-10-24       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.